Influence of ABO blood groups on primary hemostasis

Moeller, Ansgar; Weippert-Kretschmer, M.; Prinz, Helge; Kretschmer, V.

doi:10.1046/j.1537-2995.2001.41010056.x

Cited by 110 publications

(73 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[24][25][26] The local and systemic effects of long-and short-term ASA therapy have extensively been investigated. [4][5][6][7]12,13 New antithrombotic agents, like thienopyridines, have recently been developed but lack long-term follow-up results and data concerning intra-and interindividual variability. In order to guarantee optimal secondary prophylactic therapy for the prevention of vascular events after PTA, a test for monitoring antiplatelet therapy, especially for detecting 'non-responders ' would be favorable.…”

Section: Discussionmentioning

confidence: 99%

Monitoring of antiplatelet therapy with the PFA-100® in peripheral angioplasty patients

et al. 2002

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Monitoring of antiplatelet therapy with the PFA-100® in peripheral angioplasty patients

et al. 2002

View full text Add to dashboard Cite

show abstract

“…However, in the last decade, the interest of PFA-100 has often been called into question, since, although its sensitivity appears to be high, its specificity is low and includes a number of factors that may modify the results [10,11]. A metaanalysis has shown the system to be successful in detecting VWD [12].…”

Section: Introductionmentioning

confidence: 99%

Platelet function analyser (PFA‐100) results and von Willebrand factor deficiency: a 16‐year ‘real‐world’ experience

Ardillon¹,

Ternisien²,

Fouassier³

et al. 2015

Haemophilia

View full text Add to dashboard Cite

The platelet function analyser (PFA-100) is a biological tool designed to explore primary haemostasis. This system has thus been widely demonstrated as reliable in detecting von Willebrand factor (VWF) deficiency. However, most studies were based on patients benefitting from regular medical care and accurate diagnosis, and it would seem probable that the results were somewhat optimistic, and do not reflect its performances in 'real-world' situations. We have chosen to study the reliability of PFA-100 for screening VWF ristocetin cofactor (VWF:RCo) deficiency. We retrospectively analysed the results (n = 6431) of 4027 patients referred to our centre between October 1997 and June 2013 and in whom PFA-Epi, PFA-ADP, and VWF:RCo activity had been evaluated. We studied the influence of blood group on the results and the performances of each method in a subgroup of 213 patients with genetically confirmed von Willebrand disease. We have shown that the PFA-100 system, in our experience, constitutes an excellent screening test for detecting VWF:RCo deficiency, whatever the clinical situation, in 'real-world' conditions. The negative predictive value (NPV), the positive predictive value, the sensitivity and the specificity were respectively: 0.98, 0.51, 0.98 and 0.40. When values adjusted for blood group are used, NPV and sensitivity are inferior to those using normal values which have not been adjusted for blood group. We have shown the PFA-100 method to be more efficient in screening for VWF deficiency than the VWF:RCo technique.

show abstract

“…It has been consistently found that individuals with the O blood group have lower vWF levels on average than individuals with other blood groups, although the mechanism by which this occurs is unclear. Some studies (Moeller et al, 2001) have suggested that the ABO antigens influence the rate of proteolysis or clearance of the vWF molecule.…”

Section: Introductionmentioning

confidence: 99%

Genetic Variants Associated with von Willebrand Factor Levels in Healthy Men and Women Identified Using the HumanCVD BeadChip

Zabaneh

Gaunt²,

Drenos³

et al. 2011

Annals of Human Genetics

View full text Add to dashboard Cite

SummaryWe have used the gene-centric Illumina HumanCVD BeadChip to identify common genetic determinants of Von Willebrand factor (vWF) levels in healthy men and women.The Whitehall II (WHII) study (n = 5592) and the British Women's Heart and Health Study (BWHHS) (n = 3445) were genotyped using the HumanCVD BeadChip. Replication was conducted in the British Regional Heart Study (n = 3897) and 1958 Birth Cohort (n = 5048).We identified 48 single nucleotide polymorphisms (SNPs) in four genes/regions associated with vWF at P < 10 −4 . These included 19 SNPs at the ABO blood group locus with the lead variant being rs657152 (P = 9.7 × 10 −233 ). The lead variant in the 24 VWF SNPs was rs1063856 (P = 2.3 × 10 −20 ). SNPs at ESR1 (rs6909023) and NRG1( rs1685103) showed modest associations with vWF, but these were not confirmed in a meta-analysis. Using variable selection, five SNPs at the locus for ABO and two for VWF were found to have independent associations with vWF levels. After adjustment for age and gender, the selected ABO SNPs explained 15% and the VWF SNPs an additional 2% of the variance in vWF levels. Individuals at opposite tails of the additive seven SNP allele score exhibited substantial differences in vWF levels. These data demonstrate that multiple common alleles with small effects make, in combination, important contributions to individual differences in vWF levels.

show abstract

Influence of ABO blood groups on primary hemostasis

Abstract: Significant ABO-group-specific differences in nonvascular primary hemostasis could be found by IVBT. The differences are small, however, and lie within the normal range. Whether these differences have any biologic relevance can only be speculated.

Cited by 110 publications

References 38 publications

Monitoring of antiplatelet therapy with the PFA-100® in peripheral angioplasty patients

Monitoring of antiplatelet therapy with the PFA-100® in peripheral angioplasty patients

Platelet function analyser (PFA‐100) results and von Willebrand factor deficiency: a 16‐year ‘real‐world’ experience

Genetic Variants Associated with von Willebrand Factor Levels in Healthy Men and Women Identified Using the HumanCVD BeadChip

Contact Info

Product

Resources

About